AM-Pharma Returns to Clinic with Kidney Injury Drug
By Nuala Moran
Friday, September 20, 2013
LONDON – Two years after halting development of bovine alkaline phosphatase, AM-Pharma is back in the clinic with its new, proprietary, recombinant human version of the anti-inflammatory enzyme.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.